STOCK TITAN
  1. Home
  2. Sec-filings
  3. THAR
  4. [EFFECT] Tharimmune, Inc. SEC Filing

[EFFECT] Tharimmune, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
EFFECT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: July 9, 2025 5:00 P.M.
Form: S-3
CIK: 0001861657
Company Name: Tharimmune, Inc.
File Number: 333-288518

Source: View Original Filing on SEC EDGAR

Stock THAR logo
Tharimmune Inc

NASDAQ:THAR

THAR Rankings

#5876 Ranked by Market Cap
N/A Ranked by Dividends

THAR Latest News

Aug 20, 2025
Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Treatments
Aug 13, 2025
Tharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized Fentanyl
Aug 5, 2025
Nancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors
Aug 4, 2025
Tharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral Antibody Delivery
Jul 23, 2025
Tharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants

THAR Latest SEC Filings

Oct 10, 2025
[8-K] Tharimmune, Inc. Reports Material Event
Oct 9, 2025
[8-K] Tharimmune, Inc. Reports Material Event
Oct 6, 2025
[8-K] Tharimmune, Inc. Reports Material Event
Sep 18, 2025
[DEF 14A] Tharimmune, Inc. Definitive Proxy Statement
Sep 18, 2025
[DEF 14A] Tharimmune, Inc. Definitive Proxy Statement

THAR Stock Data

21.52M
4.74M
17.13%
1.5%
12.08%
Biotechnology
Pharmaceutical Preparations
Link
United States
BRIDGEWATER